{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:38:00Z","timestamp":1788550680386,"version":"build-2803163510"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The Interleukin-2 Family contains six kinds of cytokines, namely IL-2, IL-15, IL-4, IL-7, IL-9, and IL-21, all of which share a common \u03b3 chain. Many cytokines of the IL-2 family have been reported to be a driving force in immune cells activation. Therefore, researchers have tried various methods to study the anti-tumor effect of cytokines for a long time. However, due to the short half-life, poor stability, easy to lead to inflammatory storms and narrow safety treatment window of cytokines, this field has been tepid. In recent years, with the rapid development of protein engineering technology, some engineered cytokines have a significant effect in tumor immunotherapy, showing an irresistible trend of development. In this review, we will discuss the current researches of the IL-2 family and mainly focus on the application and achievements of engineered cytokines in tumor immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1090311","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:17:08Z","timestamp":1677737828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["The application of Interleukin-2 family cytokines in tumor immunotherapy research"],"prefix":"10.3389","volume":"14","author":[{"given":"Yangyihua","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiqi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.12688\/f1000research.12202.1","article-title":"The \u03b3 (C) family of cytokines: Fine-tuning signals from il-2 and il-21 in the regulation of the immune response","volume":"6","author":"Spolski","year":"2017","journal-title":"F1000Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.018","article-title":"The il-2 cytokine family in cancer immunotherapy","volume":"25","author":"Sim","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor \u0393 chain family of cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217814","article-title":"Investigation of the impact from il-2, il-7, and il-15 on the growth and signaling of activated Cd4(+) T cells","volume":"21","author":"Coppola","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2015.0054","article-title":"Stat5 in cancer and immunity","volume":"36","author":"Rani","year":"2016","journal-title":"J Interferon Cytokine Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101307","article-title":"Common gamma chain cytokines and Cd8 T cells in cancer","volume":"42","author":"Shourian","year":"2019","journal-title":"Semin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.028","article-title":"The \u0393(C) family of cytokines: Basic biology to therapeutic ramifications","volume":"50","author":"Leonard","year":"2019","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2018.05.002","article-title":"The role of the common gamma-chain family cytokines in \u0393\u03b4 T cell-based anti-cancer immunotherapy","volume":"41","author":"Van Acker","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-017-0721-9","article-title":"Tumor-related interleukins: Old validated targets for new anti-cancer drug development","volume":"16","author":"Setrerrahmane","year":"2017","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109044","article-title":"Modeling cell-specific dynamics and regulation of the common gamma chain cytokines","volume":"35","author":"Farhat","year":"2021","journal-title":"Cell Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-021-01064-4","article-title":"Cytokines in the treatment of melanoma","volume":"23","author":"Bentebibel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2002214","DOI":"10.1002\/adhm.202002214","article-title":"Engineered cytokines for cancer and autoimmune disease immunotherapy","volume":"10","author":"Uricoli","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-319-53156-4_2","article-title":"Interleukin-2: Old and new approaches to enhance immune-therapeutic efficacy","volume":"995","author":"Dhupkar","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/35105066","article-title":"Cytokines and immunodeficiency diseases","volume":"1","author":"Leonard","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.0105-2896.2005.00223.x","article-title":"Severe combined immunodeficiency. a model disease for molecular immunology and therapy","volume":"203","author":"Fischer","year":"2005","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.13.5069","article-title":"Recombinant interleukin 2 therapy in severe combined immunodeficiency disease","volume":"86","author":"Pahwa","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/352621a0","article-title":"Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting","volume":"352","author":"Schorle","year":"1991","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by Gamma(C) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting il-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"Il-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1382472","article-title":"High-dose interleukin-2 (Il-2) for the treatment of melanoma: Safety considerations and future directions","volume":"16","author":"Marabondo","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-med-073118-011031","article-title":"Engineering il-2 to give new life to T cell immunotherapy","volume":"72","author":"Overwijk","year":"2021","journal-title":"Annu Rev Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-15-0195","article-title":"Il2 variant circumvents icos+ regulatory T-cell expansion and promotes nk cell activation","volume":"4","author":"Sim","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","article-title":"Natural and modified il-2 for the treatment of cancer and autoimmune diseases","volume":"206","author":"Mizui","year":"2019","journal-title":"Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00133-0","article-title":"Cd25-T(Reg)-Depleting antibodies preserving il-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"367ra166","DOI":"10.1126\/scitranslmed.aag3187","article-title":"Improved cancer immunotherapy by a Cd25-mimobody conferring selectivity to human interleukin-2","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 'Superkine'","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of il-2 and il-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673","article-title":"Alks 4230: A novel engineered il-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000612","article-title":"Pharmacokinetics and pharmacodynamic effects of nemvaleukin Alfa, a selective agonist of the intermediate-affinity il-2 receptor, in cynomolgus monkeys","volume":"379","author":"Lopes","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1685489","article-title":"Bempegaldesleukin (Nktr-214): A cd-122-Biased il-2 receptor agonist for cancer immunotherapy","volume":"19","author":"Doberstein","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-1631","article-title":"Nktr-214, an engineered cytokine with biased Il2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-1495","article-title":"A first-in-Human study and biomarker analysis of nktr-214, a novel Il2r\u03b2\u03b3-biased cytokine, in patients with advanced or metastatic solid tumors","volume":"9","author":"Bentebibel","year":"2019","journal-title":"Cancer Discovery"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1490019","article-title":"Il-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"Of1","DOI":"10.1158\/2159-8290.Cd-nb2019-036","article-title":"Bempegaldesleukin stimulates immune response","volume":"9","year":"2019","journal-title":"Cancer Discovery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-1510","article-title":"Bempegaldesleukin (Nktr-214) plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, efficacy, and immune activation (Pivot-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discovery"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered il-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat Commun"},{"key":"B40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"N Biotechnol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.4.1428","article-title":"Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells","volume":"89","author":"Gillies","year":"1992","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.5112","article-title":"Recombinant anti-human Her2\/Neu Igg3-(Gm-Csf) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity","volume":"165","author":"Dela Cruz","year":"2000","journal-title":"J Immunol"},{"key":"B43","first-page":"4998","article-title":"A chimeric lym-1\/Interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake","volume":"56","author":"Hu","year":"1996","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.04.005","article-title":"Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature","volume":"39","author":"B\u00f6rschel","year":"2015","journal-title":"Leuk Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e1277306","DOI":"10.1080\/2162402x.2016.1277306","article-title":"Cergutuzumab amunaleukin (Cea-Il2v), a cea-targeted il-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional il-2-Based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp Alfa (Fap-Il2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"MAbs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1238538","article-title":"Human and murine Il2 receptors differentially respond to the human-Il2 component of immunocytokines","volume":"8","author":"Perez Horta","year":"2019","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001262","article-title":"Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model","volume":"8","author":"Baniel","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e5","article-title":"Advancements of common gamma-chain family cytokines in cancer immunotherapy","volume":"22","author":"Wolfarth","year":"2022","journal-title":"Immune Netw"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00868","article-title":"Il-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80246-0","article-title":"Il-15: A pleiotropic cytokine with diverse Receptor\/Signaling pathways whose expression is controlled at multiple levels","volume":"4","author":"Tagaya","year":"1996","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00429-6","article-title":"Il-15ralpha recycles and presents il-15 in trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021836","article-title":"Interleukin (Il)-15r[Alpha]-Deficient natural killer cells survive in normal but not il-15r[Alpha]-Deficient mice","volume":"197","author":"Koka","year":"2003","journal-title":"J Exp Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1586\/1744666x.2014.973856","article-title":"Interleukin-15 in the treatment of cancer","volume":"10","author":"Waldmann","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.200363097","article-title":"Il-2-Induced activation-induced cell death is inhibited in il-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B58","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(02)03668-2","article-title":"Mechanisms involved in interleukin-15-Induced suppression of human neutrophil apoptosis: Role of the anti-apoptotic mcl-1 protein and several kinases including janus kinase-2, P38 mitogen-activated protein kinase and extracellular signal-regulated kinases-1\/2","volume":"532","author":"Pelletier","year":"2002","journal-title":"FEBS Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040837","article-title":"Heterodimeric il-15 in cancer immunotherapy","volume":"13","author":"Bergamaschi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4172\/1747-0862.1000085","article-title":"Il-15 agonists: The cancer cure cytokine","volume":"7","author":"Wu","year":"2013","journal-title":"J Mol Genet Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384362","article-title":"Circulating il-15 exists as heterodimeric complex with soluble il-15r\u03b1 in human and mouse serum","volume":"120","author":"Bergamaschi","year":"2012","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0600240103","article-title":"Converting il-15 to a superagonist by binding to soluble il-15r{Alpha}","volume":"103","author":"Rubinstein","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","article-title":"Immunobiology of the il-15\/Il-15r\u03b1 complex as an antitumor and antiviral agent","volume":"38","author":"Guo","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508624200","article-title":"Soluble interleukin-15 receptor alpha (Il-15r alpha)-sushi as a selective and potent agonist of il-15 action through il-15r Beta\/Gamma. hyperagonist il-15 X il-15r alpha fusion proteins","volume":"281","author":"Mortier","year":"2006","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001428","article-title":"Interleukin-15 and cancer: Some solved and many unsolved questions","volume":"8","author":"Fiore","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1393597","article-title":"Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15","volume":"7","author":"Ochoa","year":"2018","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"734-749","DOI":"10.1038\/s41417-021-00352-2","article-title":"Cytokine-enhanced cytolytic activity of exosomes from nk cells","volume":"29","author":"Enomoto","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0444-2","article-title":"Il-2 and il-15 induced Nkg2d, Cd158a and Cd158b expression on T, nkt- like and nk cell lymphocyte subsets from regional lymph nodes of melanoma patients","volume":"26","author":"Vuleti\u0107","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-20-1002","article-title":"A fusion protein complex that combines il-12, il-15, and il-18 signaling to induce memory-like nk cells for cancer immunotherapy","volume":"9","author":"Becker-Hapak","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00543-4","article-title":"Tumor-conditional il-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"66-77","DOI":"10.1016\/j.ymthe.2022.08.016","article-title":"A novel anti-Pd-L1\/Il-15 immunocytokine overcomes resistance to pd-L1 blockade and elicits potent antitumor immunity","volume":"31","author":"Shi","year":"2022","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02749-8","article-title":"Il-15 superagonist n-803 improves ifn\u03b3 production and killing of leukemia and ovarian cancer cells by Cd34(+)\u2009Progenitor-derived nk cells","volume":"70","author":"Van der Meer","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-019-0551-y","article-title":"Mechanisms involved in il-15 superagonist enhancement of anti-Pd-L1 therapy","volume":"7","author":"Knudson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002024","article-title":"Nktr-255, a novel polymer-conjugated rhil-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci144365","article-title":"Nktr-255 is a polymer-conjugated il-15 with unique mechanisms of action on T and natural killer cells","volume":"131","author":"Robinson","year":"2021","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci152857","article-title":"Insights into the anticancer mechanisms of interleukin-15 from engineered cytokine therapies","volume":"131","author":"Bernstein","year":"2021","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0576","article-title":"Phase I study protocol: Nktr-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies","volume":"17","author":"Shah","year":"2021","journal-title":"Future Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in nk cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.11.6015","article-title":"Cutting edge: Stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma","volume":"165","author":"Ostrand-Rosenberg","year":"2000","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.11.005","article-title":"Increased il-21\/Il-21r expression and its proinflammatory effects in autoimmune thyroid disease","volume":"72","author":"Guan","year":"2015","journal-title":"Cytokine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-624585","article-title":"Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma","volume":"126","author":"Bhatt","year":"2015","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1511711112","article-title":"Opposing roles of Stat1 and Stat3 in il-21 function in Cd4+ T cells","volume":"112","author":"Wan","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature05970","article-title":"Il-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ncomms1475","article-title":"In-vitro derived germinal centre b cells differentially generate memory b or plasma cells in vivo","volume":"2","author":"Nojima","year":"2011","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper Cd4 T cells (Tfh)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061263","article-title":"Harnessing the il-21-Batf pathway in the Cd8(+) T cell anti-tumor response","volume":"13","author":"Topchyan","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401236","article-title":"A context-dependent role for il-21 in modulating the differentiation, distribution, and abundance of effector and memory Cd8 T cell subsets","volume":"196","author":"Tian","year":"2016","journal-title":"J Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089375","article-title":"Il-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific Cd8+ cytotoxic T lymphocytes","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/696578","article-title":"Il-21: A pleiotropic cytokine with potential applications in oncology","volume":"2015","author":"Croce","year":"2015","journal-title":"J Immunol Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800550","article-title":"Il-21 enhances the development of colitis-associated colon cancer: Possible involvement of activation-induced cytidine deaminase expression","volume":"202","author":"Araki","year":"2019","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.648293","article-title":"Il-21 is an accomplice of pd-L1 in the induction of pd-1-Dependent treg generation in head and neck cancer","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-07-0410","article-title":"An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma","volume":"13","author":"Davis","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.599","article-title":"A phase 1 trial of recombinant human il-21 in combination with cetuximab in patients with metastatic colorectal cancer","volume":"106","author":"Steele","year":"2012","journal-title":"Br J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-0456","article-title":"A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade b-cell lymphoproliferative disorders","volume":"18","author":"Timmerman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2019.4354","article-title":"Il\u221221\/Il\u221221r inhibit tumor growth and invasion in Non\u2212Small cell lung cancer cells Via suppressing Wnt\/\u0392\u2212Catenin signaling and Pd\u2212L1 expression","volume":"44","author":"Xue","year":"2019","journal-title":"Int J Mol Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8262989","article-title":"Irradiated bladder cancer cells expressing both gm-csf and il-21 versus either gm-csf or il-21 alone as tumor vaccine in a mouse xenograft model","volume":"2019","author":"Peng","year":"2019","journal-title":"BioMed Res Int"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"Cd4(+) T cell help is required for the formation of a cytolytic Cd8(+) T cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02730.x","article-title":"Interleukin-21 activates human natural killer cells and modulates their surface receptor expression","volume":"123","author":"Skak","year":"2008","journal-title":"Immunology"},{"key":"B101","first-page":"13","article-title":"Comparison of vascular leak syndrome in mice treated with Il21 or Il2","volume":"63","author":"Sivakumar","year":"2013","journal-title":"Comp Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132000","article-title":"Targeting tumors with il-21 reshapes the tumor microenvironment by proliferating pd-1inttim-3-Cd8+ T cells","volume":"5","author":"Deng","year":"2020","journal-title":"JCI Insight"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738211","article-title":"Anti-Cd20-Interleukin-21 fusokine targets malignant b cells Via direct apoptosis and nk-Cell-Dependent cytotoxicity","volume":"129","author":"Bhatt","year":"2017","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41467-021-21241-0","article-title":"Targeting il-21 to tumor-reactive T cells enhances memory T cell responses and anti-Pd-1 antibody therapy","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00832","article-title":"Engineered il-21 cytokine muteins fused to anti-Pd-1 antibodies can improve Cd8+ T cell function and anti-tumor immunity","volume":"11","author":"Shen","year":"2020","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108307","article-title":"An engineered il-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with pd-1 or tigit blockade","volume":"101","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.Ccr-16-0004","article-title":"Il-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells","volume":"23","author":"McMichael","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152021","article-title":"Combined il-21-Primed polyclonal ctl plus Ctla4 blockade controls refractory metastatic melanoma in a patient","volume":"213","author":"Chapuis","year":"2016","journal-title":"J Exp Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.2.703","article-title":"Interleukin 5 synthesis by eosinophils: Association with granules and immunoglobulin-dependent secretion","volume":"179","author":"Dubucquoi","year":"1994","journal-title":"J Exp Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1021\/bi00220a011","article-title":"Disulfide assignments in recombinant mouse and human interleukin 4","volume":"30","author":"Carr","year":"1991","journal-title":"Biochemistry"},{"key":"B111","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2015.04.012","article-title":"The evolution of il-4 and il-13 and their receptor subunits","volume":"75","author":"Wang","year":"2015","journal-title":"Cytokine"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802465105","article-title":"Distinct roles for il-13 and il-4 Via il-13 receptor Alpha1 and the type ii il-4 receptor in asthma pathogenesis","volume":"105","author":"Munitz","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ni1544","article-title":"Unique functions of the type ii interleukin 4 receptor identified in mice lacking the interleukin 13 receptor Alpha1 chain","volume":"9","author":"Ramalingam","year":"2008","journal-title":"Nat Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: An update on interleukin (Il)-4 and il-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062998","article-title":"Involvement of il-4, il-13 and their receptors in pancreatic cancer","volume":"22","author":"Shi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxab080","article-title":"The role of il-4 derived from follicular helper T (Tfh) cells and type 2 helper T (Th2) cells","volume":"33","author":"Kubo","year":"2021","journal-title":"Int Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2018.1520095","article-title":"Recent developments in the use of biologics targeting il-5, il-4, or il-13 in severe refractory asthma","volume":"12","author":"Walsh","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2019.1655649","article-title":"Elevated serum level of il-4 in neuromyelitis optica and multiple sclerosis patients","volume":"40","author":"Tahani","year":"2019","journal-title":"J Immunoassay Immunochem"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.10.204","article-title":"Characterization of cryptic allosteric site at il-4r\u03b1: New paradigm towards il-4\/Il-4r inhibition","volume":"123","author":"Naz","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3216","article-title":"Hodgkin Lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model","volume":"105","author":"Kawakami","year":"2005","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3109\/07357909309018879","article-title":"Interleukin-4 and cancer therapy","volume":"11","author":"Puri","year":"1993","journal-title":"Cancer Invest"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1723","article-title":"Interleukin-4 and cpg oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses","volume":"27","author":"Kajiwara","year":"2012","journal-title":"Oncol Rep"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1096","article-title":"Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines","volume":"8","author":"Junttila","year":"2012","journal-title":"Nat Chem Biol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/1061186x.2020.1764964","article-title":"Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor","volume":"28","author":"Bai","year":"2020","journal-title":"J Drug Target"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278644","article-title":"Il4-Stat6 signaling induces Cd20 in chronic lymphocytic leukemia and this axis is repressed by Pi3k\u03b4 inhibitor idelalisib","volume":"106","author":"Sandova","year":"2021","journal-title":"Haematologica"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020727","article-title":"Possible roles of interleukin-4 and -13 and their receptors in gastric and colon cancer","volume":"22","author":"Song","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153477","article-title":"Stat6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology","volume":"223","author":"Karpathiou","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.05.004","article-title":"Cell biology of il-7, a key lymphotrophin","volume":"16","author":"Jiang","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.4.1073","article-title":"Murine interleukin 7 (Il-7) receptor. characterization on an il-7-Dependent cell line","volume":"171","author":"Park","year":"1990","journal-title":"J Exp Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/science.8266077","article-title":"Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor","volume":"262","author":"Noguchi","year":"1993","journal-title":"Science"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1126\/science.8128231","article-title":"Functional participation of the il-2 receptor gamma chain in il-7 receptor complexes","volume":"263","author":"Kondo","year":"1994","journal-title":"Science"},{"key":"B132","doi-asserted-by":"publisher","first-page":"ra77","DOI":"10.1126\/scisignal.2002246","article-title":"The long-term survival potential of mature T lymphocytes is programmed during development in the thymus","volume":"4","author":"Sinclair","year":"2011","journal-title":"Sci Signal"},{"key":"B133","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.2.677","article-title":"Thymic stromal lymphopoietin: A cytokine that promotes the development of igm+ b cells in vitro and signals Via a novel mechanism","volume":"162","author":"Levin","year":"1999","journal-title":"J Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/science.1631559","article-title":"Cloning of the gamma chain of the human il-2 receptor","volume":"257","author":"Takeshita","year":"1992","journal-title":"Science"},{"key":"B135","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-030-55617-4_2","article-title":"Interleukin (Il)-7 signaling in the tumor microenvironment","volume":"1290","author":"Bednarz-Misa","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5466.675","article-title":"Control of homeostasis of Cd8+ memory T cells by opposing cytokines","volume":"288","author":"Ku","year":"2000","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.04.003","article-title":"Interleukin-7 enhances anti-tumor activity of Cd8(+) T cells in patients with hepatocellular carcinoma","volume":"118","author":"Teng","year":"2019","journal-title":"Cytokine"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/80868","article-title":"Interleukin-7 mediates the homeostasis of na\u00efve and memory Cd8 T cells in vivo","volume":"1","author":"Schluns","year":"2000","journal-title":"Nat Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"Il-7 and Ccl19 expression in car-T cells improves immune cell infiltration and car-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-0947","article-title":"Long-acting recombinant human interleukin-7, nt-I7, increases cytotoxic Cd8 T cells and enhances survival in mouse glioma models","volume":"28","author":"Campian","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01557","article-title":"Modulation of signaling mediated by tslp and il-7 in inflammation, autoimmune diseases, and cancer","volume":"11","author":"Markovi\u0107","year":"2020","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0479-x","article-title":"Flip the coin: Il-7 and il-7r in health and disease","volume":"20","author":"Barata","year":"2019","journal-title":"Nat Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6934","article-title":"Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity","volume":"85","author":"Uyttenhove","year":"1988","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003049","article-title":"A brief history of il-9","volume":"186","author":"Goswami","year":"2011","journal-title":"J Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.immuni.2015.08.020","article-title":"Induction of interleukin-9-Producing mucosal mast cells promotes susceptibility to ige-mediated experimental food allergy","volume":"43","author":"Chen","year":"2015","journal-title":"Immunity"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130071","article-title":"Il-9-Mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation","volume":"210","author":"Turner","year":"2013","journal-title":"J Exp Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat5943","article-title":"Human \"T(H)9\" cells are a subpopulation of ppar-\u0393(+) T(H)2 cells","volume":"4","author":"Micoss\u00e9","year":"2019","journal-title":"Sci Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4049\/jimmunol.1001183","article-title":"Il-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression","volume":"186","author":"Eller","year":"2011","journal-title":"J Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830191130","article-title":"Tcgf Iii\/P40 is produced by naive murine Cd4+ T cells but is not a general T cell growth factor","volume":"19","author":"Schmitt","year":"1989","journal-title":"Eur J Immunol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812530106","article-title":"Il-9 induces differentiation of Th17 cells and enhances function of Foxp3+ natural regulatory T cells","volume":"106","author":"Elyaman","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/7.1.115","article-title":"Sharing of the il-2 receptor gamma chain with the functional il-9 receptor complex","volume":"7","author":"Kimura","year":"1995","journal-title":"Int Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-030-38315-2_3","article-title":"Il-9 and Th9 cells in tumor immunity","volume":"1240","author":"He","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jaci.2018.06.046","article-title":"B lymphocyte-induced maturation protein 1 controls T(H)9 cell development, il-9 production, and allergic inflammation","volume":"143","author":"Benevides","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00665-6","article-title":"The role of interleukin-9 in cancer","volume":"26","author":"Lee","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3922","article-title":"Glucocorticoid-induced tumor necrosis factor receptor-related protein Co-stimulation facilitates tumor regression by inducing il-9-Producing helper T cells","volume":"21","author":"Kim","year":"2015","journal-title":"Nat Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1177\/1533033819857737","article-title":"Il-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironment in vivo","volume":"18","author":"Wang","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"B157","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00281-016-0599-4","article-title":"T(H)9 cells in anti-tumor immunity","volume":"39","author":"Rivera Vargas","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23930","article-title":"Il-9 inhibits htb-72 melanoma cell growth through upregulation of P21 and trail","volume":"111","author":"Fang","year":"2015","journal-title":"J Surg Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1710413","article-title":"Targeting the il-9 pathway in cancer immunotherapy","volume":"16","author":"Zheng","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: Challenges and opportunities for il-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1090311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T06:17:14Z","timestamp":1677737834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1090311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":160,"alternative-id":["10.3389\/fimmu.2023.1090311"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1090311","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"article-number":"1090311"}}